摘要
目的探讨氟伏沙明合并舒必利治疗抑郁症的临床疗效及安全性。方法将87例符合条件的抑郁症患者随机分为氟伏沙明联合舒必利组（观察组）及单用氟伏沙明组（对照组）,疗程8周。用4级临床疗效、汉密尔顿抑郁量表（HAM D）、简明精神病量表（BPRS）观察疗效,用副反应量表（TESS）评定不良反应。结果治疗8周后2组BPRS、HAM D总分及因子分都较治疗前明显降低,差异有统计学意义（P=0.009）;氟伏沙明联合舒必利组痊愈率显著高于单用氟伏沙明,差异有统计学意义（2χ=43.85,P〈0.05）;观察组BPRS的思维障碍、激活性、敌对猜疑因子分和总分治疗8周后明显低于对照组,差异有统计学意义（t=3.48,5.32,4.21,6.75;P〈0.05）;观察组H AM D的睡眠障碍和总分明显低于对照组,差异有统计学意义（t=11.32,7.75;P〈0.01）。结论氟伏沙明联合小剂量舒必利治疗抑郁症疗效优于单用氟伏沙明,不良反应少。
Objective To study the efficacy and safety of Sulpiride combined Fluvoxamine in treatment of depression.Methods A total of 87 patients eligible for depression were randomly assigned to Fluvoxamine combined Sulpiride group（observation group） and Fluvoxamine alone（control group） for 8 weeks.Clinical efficacy was evaluated with the four stage clinical effectiveness,HAMD,BPRS scale,adverse reactions were evaluated with the TESS scale.Results After 8 weeks,BPRS,HAMD total score and factor scores of two groups were significantly lower than those before treatment,the difference was statistically significant（P0.01）;the cure rate of Fluvoxamine combined Sulpiride group was significantly higher than that of Fluvoxamine alone,the difference was statistically significant（P0.05）;BPRS thought disorder,activation of hostile suspicion factor scores and total score of the observation group were significantly lower than the control group by t-test,the difference was statistically significant（P0.05）;HAMD retardation,body mass factor scores and total score of observation group were significantly lower than the control group by t-test,the difference was statistically significant（P0.05）.Conclusion Fluvoxamine combined with low dose Sulpiride is more effective than fluvoxamine alone in treatment of depression,the adverse reactions are fewer.
出处
《中国健康心理学杂志》
2011年第7期789-791,共3页
China Journal of Health Psychology
